LEQEMBI is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Eisai Inc.. The primary component is Lecanemab.
Product ID | 62856-212_aff5d037-645b-4220-95e5-8ac9775f92a0 |
NDC | 62856-212 |
Product Type | Human Prescription Drug |
Proprietary Name | LEQEMBI |
Generic Name | Lecanemab |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVENOUS |
Marketing Start Date | 2023-01-06 |
Marketing Category | BLA / |
Application Number | BLA761269 |
Labeler Name | Eisai Inc. |
Substance Name | LECANEMAB |
Active Ingredient Strength | 100 mg/mL |
NDC Exclude Flag | N |
Listing Certified Through | 2024-12-31 |
Marketing Start Date | 2023-01-06 |
NDC Exclude Flag | N |
Sample Package? | N |
NDC | Brand Name | Generic Name |
---|---|---|
62856-212 | LEQEMBI | lecanemab |
62856-215 | LEQEMBI | lecanemab |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
LEQEMBI 97151804 not registered Live/Pending |
Eisai R&D Management Co., Ltd. 2021-12-01 |